NTLA
VENTE TOTALE: 22 675 titres (~286 819,00 $ US)
- Insiders
- LEONARD JOHN M
- Total bought
- —
- Total sold
- $286,819
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-27
NTLA combines a weak catalyst score (20) with deteriorating fundamentals (trend score: 25), reflecting a pre-revenue biotech burning cash with no near-term path to profitability.
The first sentence of the analysis written for NTLA on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.5% | 82.2% | 75.3% | 85.5% | 79.2% | |
| Ebit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Ebitda Margin | -586.3% | -879.0% | -1301.8% | -895.3% | -789.6% | |
| Operating Profit Margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | |
| Pretax Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Continuous Operations Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Net Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Bottom Line Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Current Ratio | 5.080 | 5.772 | 8.665 | 9.615 | 6.114 | |
| Quick Ratio | 5.080 | 5.772 | 8.665 | 9.615 | 6.114 | |
| Solvency Ratio | -2.324 | -1.594 | -1.883 | -1.640 | -1.027 | |
| Cash Ratio | 1.497 | 1.707 | 1.968 | 4.137 | 0.981 | |
| Price To Earnings Ratio | -2.360 | -2.221 | -5.625 | -5.664 | -31.280 | |
| Price To Earnings Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Forward Price To Earnings Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Price To Earnings Diluted Ratio | -2.360 | -2.221 | -5.625 | -5.664 | -31.280 | |
| Price To Earnings Diluted Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Price To Book Ratio | 1.451 | 1.322 | 2.577 | 2.174 | 8.058 | |
| Price To Sales Ratio | 14.398 | 19.914 | 74.613 | 51.525 | 253.608 | |
| Price To Free Cash Flow Ratio | -2.747 | -3.250 | -6.633 | -6.857 | -35.252 | |
| Price To Operating Cash Flow Ratio | -2.793 | -3.304 | -6.868 | -8.058 | -37.251 | |
| Debt To Assets Ratio | 0.111 | 0.176 | 0.089 | 0.086 | 0.057 | |
| Debt To Equity Ratio | 0.139 | 0.241 | 0.110 | 0.106 | 0.071 | |
| Debt To Capital Ratio | 0.122 | 0.194 | 0.099 | 0.096 | 0.066 | |
| Long Term Debt To Capital Ratio | 0.091 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.254 | 1.366 | 1.239 | 1.230 | 1.244 | |
| Working Capital Turnover Ratio | 0.142 | 0.082 | 0.037 | 0.060 | 0.055 | |
| Operating Cash Flow Ratio | -3.358 | -3.147 | -3.421 | -2.634 | -1.788 | |
| Operating Cash Flow Sales Ratio | -5.156 | -6.028 | -10.864 | -6.394 | -6.808 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 1.017 | 1.035 | 1.175 | 1.057 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.738 | -1.660 | -3.417 | -2.550 | -3.040 | |
| Capital Expenditure Coverage Ratio | -60.381 | -60.381 | -28.179 | -5.708 | -17.641 | |
| Dividend Paid And Capex Coverage Ratio | -60.381 | -60.381 | -28.179 | -5.708 | -17.641 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.299 | -2.307 | -5.496 | -4.914 | -31.928 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.5% | ▼-5.8% | ▼-3.2% |
| Ebit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Ebitda Margin | -586.3% | ▲292.7% | ▲304.1% |
| Operating Profit Margin | -651.7% | ▲271.4% | ▲285.3% |
| Pretax Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Continuous Operations Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Net Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Bottom Line Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Current Ratio | 5.080 | ▼-0.693 | ▼-1.969 |
| Quick Ratio | 5.080 | ▼-0.693 | ▼-1.969 |
| Solvency Ratio | -2.324 | ▼-0.729 | ▼-0.630 |
| Cash Ratio | 1.496 | ▼-0.210 | ▼-0.561 |
| Price To Earnings Ratio | -2.360 | ▼-0.139 | ▲7.071 |
| Price To Earnings Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Forward Price To Earnings Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Price To Earnings Diluted Ratio | -2.360 | ▼-0.139 | ▲7.071 |
| Price To Earnings Diluted Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Price To Book Ratio | 1.451 | ▲0.129 | ▼-1.665 |
| Price To Sales Ratio | 14.398 | ▼-5.517 | ▼-68.414 |
| Price To Free Cash Flow Ratio | -2.747 | ▲0.503 | ▲8.200 |
| Price To Operating Cash Flow Ratio | -2.793 | ▲0.511 | ▲8.862 |
| Debt To Assets Ratio | 0.111 | ▼-0.066 | ▲0.007 |
| Debt To Equity Ratio | 0.139 | ▼-0.102 | ▲0.006 |
| Debt To Capital Ratio | 0.122 | ▼-0.072 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.091 | ▲0.091 | ▲0.072 |
| Financial Leverage Ratio | 1.254 | ▼-0.112 | ▼-0.012 |
| Working Capital Turnover Ratio | 0.142 | ▲0.060 | ▲0.067 |
| Operating Cash Flow Ratio | -3.358 | ▼-0.211 | ▼-0.489 |
| Operating Cash Flow Sales Ratio | -5.155 | ▲0.872 | ▲1.895 |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 0.000 | ▼-0.043 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -3.738 | ▼-2.078 | ▼-0.857 |
| Capital Expenditure Coverage Ratio | -60.381 | 0.000 | ▼-25.923 |
| Dividend Paid And Capex Coverage Ratio | -60.381 | 0.000 | ▼-25.923 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.299 | ▲0.008 | ▲7.090 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $974.3M | $1.15B | $2.71B | $2.69B | $8.38B | |
| Enterprise value | $912.2M | $1.17B | $2.60B | $2.29B | $8.33B | |
| EV / Sales | 13.48x | 20.28x | 71.54x | 43.99x | 252.11x | |
| EV / Op. cash flow | -2.62x | -3.36x | -6.58x | -6.88x | -37.03x | |
| EV / Free cash flow | -2.57x | -3.31x | -6.36x | -5.85x | -35.05x | |
| EV / EBITDA | -2.30x | -2.31x | -5.50x | -4.91x | -31.93x | |
| Net debt / EBITDA | 0.16x | -0.04x | 0.24x | 0.84x | 0.19x | |
| Current ratio | 5.08x | 5.77x | 8.66x | 9.62x | 6.11x | |
| Income quality | 0.67x | 0.67x | 0.82x | 0.70x | 0.84x | |
| Graham net-net | $3 | $3 | $8 | $12 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $423.8M | $529.0M | $883.1M | $1.09B | $643.5M | |
| Invested capital | $547.5M | $775.7M | $1.03B | $1.25B | $743.6M | |
| Return on assets | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% | |
| Operating ROA | -43.4% | -42.9% | -36.5% | -32.6% | -27.2% | |
| Return on tangible assets | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% | |
| Return on equity | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% | |
| Return on invested capital | -57.7% | -48.6% | -42.8% | -32.5% | -22.7% | |
| Return on capital employed | -59.7% | -49.5% | -43.5% | -32.9% | -22.9% | |
| Earnings yield | -42.4% | -45.0% | -17.8% | -17.7% | -3.2% | |
| Free cash flow yield | -36.4% | -30.8% | -15.1% | -14.6% | -2.8% | |
| Capex / Op. cash flow | -1.7% | -1.7% | -3.5% | -17.5% | -5.7% | |
| Capex / Depreciation | 56.2% | 56.2% | 155.8% | 771.1% | 185.1% | |
| Capex / Sales | 8.5% | 10.0% | 38.6% | 112.0% | 38.6% | |
| SG&A / Sales | 177.0% | 217.4% | 321.1% | 173.3% | 215.1% | |
| R&D / Sales | 574.6% | 805.7% | 1199.4% | 805.8% | 695.3% | |
| Stock comp / Sales | 228.0% | 266.6% | 369.5% | 175.4% | 142.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 51d | 54d | 367d | 26d | 22d | |
| Days payables outstanding | 464d | 518d | 303d | 248d | 511d | |
| Operating cycle | 51d | 54d | 367d | 26d | 22d | |
| Cash conversion cycle | -413d | -464d | 64d | -222d | -489d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-15.5%EV / Sales ▼-33.5%EV / EBITDA ▲+0.3%EV / Op. cash flow ▲+0.749Earnings yield ▲+0.027
Profitability
Return on equity ▼-0.019Return on assets ▼-0.054Return on invested capital ▼-0.091Return on capital employed ▼-0.103Operating ROA ▼-0.005Income quality 0.000Tax burden 0.000
Efficiency
Days sales outstanding ▼-2.644Days payables outstanding ▼-53.510Operating cycle ▼-2.644Cash conversion cycle ▲+50.866Capex / Sales ▼-0.014R&D / Sales ▼-2.311
Balance-sheet strength
Current ratio ▼-0.692Net debt / EBITDA ▲+0.198Working capital ▼-105185000.000Invested capital ▼-228232000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-88.4%EV / Sales ▼-94.7%EV / EBITDA ▲+92.8%EV / Op. cash flow ▲+34.417Earnings yield ▼-0.392
Profitability
Return on equity ▼-0.357Return on assets ▼-0.283Return on invested capital ▼-0.349Return on capital employed ▼-0.368Operating ROA ▼-0.162Income quality ▼-0.168Tax burden 0.000
Efficiency
Days sales outstanding ▲+28.640Days payables outstanding ▼-47.064Operating cycle ▲+28.640Cash conversion cycle ▲+75.704Capex / Sales ▼-0.301R&D / Sales ▼-1.206
Balance-sheet strength
Current ratio ▼-1.034Net debt / EBITDA ▼-0.033Working capital ▼-219643000.000Invested capital ▼-196128000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $15,001 - $50,000 |
| 2021-10-29 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-09-20 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-07-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-01-15 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-18 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-08-26 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-07-10 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-24 4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
- 2026-08-07 Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia''s 2024 Inducement Plan, as amended, as a material inducement to employment.
- 2026-08-07 NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues Intellia''s Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
- 2026-08-07 Intellia Therapeutics Q2 Earnings Call Highlights Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
- 2026-08-06 Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
- 2026-08-06 Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
- 2026-08-06 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.
- 2026-08-03 Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one
- 2026-07-30 Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
- 2026-07-21 Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company''s stock after selling 219,400 shares during the quarter. Amova Asset Management